Arvinas made $500K in Q3 2026 (-99% Y/Y). Operating margin n/m, net loss $53.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Revenue$500K
Year over year-99%
Operating marginn/m
Net earnings−$53.9M
Operating cash flow−$10.4M
Drawing the Sankey…
Open the interactive Sankey →click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $500K in Q3 2026, down 99% year over year and down 100% from the previous quarter.
Operating costs exceeded revenue by $59.1M, an operating margin of -11820.0%. Total costs fell 30% while revenue fell 99%. The quarter ended with a net loss of $53.9M, after a profit of $169.4M the previous quarter.
Operating cash flow was −$10.4M. Non-cash charges added back $600K of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items added $37.0M. Capital expenditures of −$200K exceeded it, leaving free cash flow of −$10.2M.
Quarterly history
Quarter
Form
Filed
Revenue
Y/Y
Op. margin
Net earnings
Op. cash flow
Q3 2026
10-Q
Nov 3, 2026
$500K
-99%
n/m
−$53.9M
−$10.4M
Q2 2026
10-Q
Aug 4, 2026
$250M
11×
65.7%
$169M
−$48.3M
Q1 2026
10-Q
May 11, 2026
$15.6M
-92%
-409.0%
−$57.6M
−$69.2M
Q4 2025
10-K
Feb 24, 2026
$9.5M
-84%
-785.3%
−$67.4M
−$30.4M
Q3 2025
10-Q
Nov 5, 2025
$41.9M
-59%
-104.5%
−$35.1M
−$59.1M
Q2 2025
10-Q
Aug 6, 2025
$22.4M
-71%
-319.2%
−$61.2M
−$95.4M
Q1 2025
10-Q
May 1, 2025
$189M
+646%
37.8%
$82.9M
−$88.9M
Charts
Latest (Q3 2026): Y/Y -99%, Q/Q -100%.From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.Latest (Q3 2026): Net income −$53.9M, Operating cash flow −$10.4M.+79.5% since FY2020: more shares outstanding (issuance, stock pay).Cash $143M, short-term investments $542M, long-term debt $600K at 2025-12-31.Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
PFE · Stated in 10-K (named, share not stated) · source
About Arvinas
We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body’s ow n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression.
In its own words, from its 10-K, filed Feb 24, 2026.
Arvinas against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -99% against the peers' median +7%.